Revenue and net profit grew year-over-year for the quarter and nine months ended December 31, 2024, with strong margins and higher EPS. Financials were reviewed and approved without modifications, and the company operates exclusively in the Pharmaceuticals segment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.